Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Brennan
    Brennan
  3. Motzer
    Motzer
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Russo
    Russo
  7. Shaha
    Shaha
  8. Vickers
    Vickers
  9. Eastham
    Eastham
  10. Scardino
    Scardino

Groups

  1. Department of Medicine (1524)
  2. Surgery (1238)
  3. Solid Tumor Oncology Division (886)
  4. Survivorship Research (815)
  5. GSK Faculty (669)
  6. Population Sciences Research Program (618)
  7. Sloan Kettering Institute Faculty (611)
  8. Department of Pathology and Laboratory Medicine (544)
  9. Epidemiology and Biostatistics (488)
  10. Center for Hematologic Malignancies (434)
Search Within
Formats
  1. Journal Article (3508)
  2. Meeting Abstract (680)
  3. Review (196)
  4. Book Section (106)
  5. Conference Paper (94)
  6. Editorial (90)
  7. Research Letter (35)
  8. Guidelines (28)
  9. Correspondence (25)
  10. Miscellaneous (5)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1524)
  2. Surgery (1238)
  3. Solid Tumor Oncology Division (886)
  4. Survivorship Research (815)
  5. GSK Faculty (669)
  6. Population Sciences Research Program (618)

More Groups

People
  1. Harry Herr (91)
  2. Murray Brennan (86)
  3. Robert Motzer (86)
  4. Jatin Shah (77)
  5. Samuel Danishefsky (74)
  6. Andrew Vickers (71)

More People

Years
  1. 2025 (115)
  2. 2024 (192)
  3. 2023 (261)
  4. 2022 (186)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1455)
  2. Journal of Surgical Oncology (374)
  3. BJU International (334)
  4. Hematological Oncology (199)
  5. Histopathology (158)
  6. EMBO Journal (131)

More Publications

Results (4770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step‐up dosing of mosunetuzumab in relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL)
    Meeting Abstract

    Sehn, L. H.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Diefenbach, C. M.; Flinn, I.; Hong, J. Y.; Kim, W. S.; Matasar, M.; Nastoupil, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical significance and outcomes in patients with diffuse large B‐cell lymphoma (DLBCL) harboring extra copies [EC] and/or translocations [TL] of MYC, BCL2, and BCL6
    Meeting Abstract

    Sermer, D.; Bobillo, S.; Seshan, V.; Dogan, A.; Younes, A.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Response to A+CHP by CD30 expression in the ECHELON‐2 trial
    Meeting Abstract

    Illidge, T.; Horwitz, S.; Iyer, S.; Bartlett, N.; Kim, W.; Tilly, H.; Belada, D.; Feldman, T.; Illés, Á; Jacobsen, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Anaplastic large cell lymphoma, ALK‐negative: Analysis of 235 cases collected by the T‐cell project
    Meeting Abstract

    Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y. H.; Manni, M.; Horwitz, S. M.; Antonio De Souza, C.; Radford, J.; Varela, S. B.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (PTS) with CD30‐positive (CD30+) cutaneous T‐cell lymphoma (CTCL)
    Meeting Abstract

    Horwitz, S. M.; Scarisbrick, J.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis in the PH 3 ECHELON‐1 study: Worse outcome with ABVD in patients with elevated baseline levels of SCD30 and TARC
    Meeting Abstract

    Radford, J.; Connors, J. M.; Younes, A.; Gallamini, A.; Ansell, S. M.; Kim, W. S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Highly favorable outcomes with RT followed by ASCT in low/low‐intermediate secondary age adjusted IPI rel/ref DLBCL patients refractory to salvage chemotherapy
    Meeting Abstract

    Yang, J. C.; Chau, K. W.; Scordo, M.; Sauter, C. S.; Yahalom, J.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save